British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

H.C. Wainwright sets a rare $0 target for Sarepta Therapeutics amid FDA scrutiny over its Duchenne muscular dystrophy gene therapy Elevidys. Read more here.

A nonprofit in Ohio is navigating uncertainty with several programs on the chopping block. Disability Rights Ohio serves as an advocate for people with disabilities.

Biogen is investing $2 billion in its U.S. manufacturing footprint — but not in Massachusetts, where the drug company is ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...

Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...